| Food-Effect, Single and Multiple Dose Pharmacokinetics, Safety and Tolerability Study of 4-MUST, 128 mg, Tablets in Healthy Volunteers (NCT07594977) | Valenta Pharm JSC | 2026-01-26 |
| Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia (NCT07595003) | Valenta Pharm JSC | 2025-12-12 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections. (NCT07420985) | Valenta Pharm JSC | 2025-10-24 |
| Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions. (NCT07645534) | Valenta Pharm JSC | 2025-07-11 |
| Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders (NCT06843044) | Valenta Pharm JSC | 2025-01-13 |
| Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers (NCT06859333) | Valenta Pharm JSC | 2025-01-13 |
| Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy Volunteers (NCT06857890) | Valenta Pharm JSC | 2024-12-09 |
| Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, Lozenges (NCT06843018) | Valenta Pharm JSC | 2024-11-14 |
| Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy Volunteers (NCT06096571) | Valenta Pharm JSC | 2024-06-15 |
| Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers (NCT06098742) | Valenta Pharm JSC | 2024-04-25 |
| Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mg (NCT06342804) | Valenta Pharm JSC | 2024-03-19 |
| Pharmacokinetics and Bioequivalence of Doxylamine+Pyridoxine and Diclectin Under Fed Conditions in Healthy Volunteers (NCT06342778) | Valenta Pharm JSC | 2024-02-27 |
| Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo (NCT06321341) | Valenta Pharm JSC | 2024-01-24 |
| Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections (NCT06315400) | Valenta Pharm JSC | 2023-12-19 |
| Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers (NCT06315387) | Valenta Pharm JSC | 2023-12-04 |
| Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections (NCT06379542) | Valenta Pharm JSC | 2023-12-04 |
| A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders (NCT05586789) | Valenta Pharm JSC | 2022-10-12 |
| Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers (NCT05558462) | Valenta Pharm JSC | 2022-08-22 |
| Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Film-coated, Enteric-soluble Tablets, and Diclectin, Delayed Release Tablets, in Healthy Volunteers (NCT05498233) | Valenta Pharm JSC | 2022-08-18 |
| A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections (NCT05544916) | Valenta Pharm JSC | 2022-08-05 |
| Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma (NCT05561816) | Valenta Pharm JSC | 2022-07-19 |
| Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection (NCT05273619) | Valenta Pharm JSC | 2022-05-23 |
| Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy Volunteers (NCT05505097) | Valenta Pharm JSC | 2022-05-04 |
| Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers (NCT05412173) | Valenta Pharm JSC | 2022-04-22 |
| Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets (NCT05295121) | Valenta Pharm JSC | 2022-02-10 |
| Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated Tablets (NCT05294250) | Valenta Pharm JSC | 2022-02-01 |
| Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo (NCT05430217) | Valenta Pharm JSC | 2022-01-28 |
| Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19 (NCT05216497) | Valenta Pharm JSC | 2021-10-06 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections (NCT05030324) | Valenta Pharm JSC | 2021-10-01 |
| Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections (NCT05269290) | Valenta Pharm JSC | 2021-09-23 |
| Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in Healthy Volunteers (NCT06552624) | Valenta Pharm JSC | 2021-07-07 |
| Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection (NCT05269329) | Valenta Pharm JSC | 2021-04-26 |